日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tet2 deficiency-induced expansion of monocyte-derived macrophages promotes liver fibrosis.

Tet2 缺乏诱导的单核细胞衍生巨噬细胞扩增促进肝纤维化。

Feng Jiuxing, Wu Baitong, Li Yu, Sun Pengli, Liu Qian, Xiao Qianxue, Cai Jia-Bin, Zheng Yimin, Chen Haonan, Xu Yichi, Liu Yixin, Shi Guo-Ming, Tan Li, Shi Yujiang Geno

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study

抗PD-1抗体托瑞普利单抗联合乐伐替尼,或吉西他滨联合化疗方案联合乐伐替尼作为晚期肝内胆管癌患者的一线治疗:一项随机、开放标签、双队列II期研究

Huang, Xiao-Yong; Shi, Guo-Ming; Zheng, Zhi-Tao; Sun, Hui-Chuan; Liang, Fei; Ji, Yuan; Chen, Yi; Yang, Guo-Huan; Hu, Zhi-Qiang; Lu, Jia-Cheng; Meng, Xian-Long; Guo, Xiao-Jun; Zhang, Chao-Chen; Fan, Jia; Zhou, Jian

Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer

赖氨酸特异性去甲基化酶1缺失重塑肿瘤微环境,从而克服肝癌中对程序性死亡受体1抑制剂治疗的获得性耐药性

Liang, Chen; Ye, Mu; Yu, Lei; Zhang, Peng-Fei; Guo, Xiao-Jun; Meng, Xian-Long; Zeng, Hai-Ying; Hu, Shu-Yang; Zhang, Dao-Han; Sun, Qi-Man; Shen, Ying-Hao; Cai, Jia-Bin; Li, Shuang-Qi; Chen, Zhen; Shi, Ying-Hong; Ke, Ai-Wu; Shi, Yujiang G; Zhou, Jian; Fan, Jia; Wu, Fei-Zhen; Huang, Xiao-Yong; Shi, Guo-Ming; Tang, Zheng; Lu, Jia-Cheng

Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

更正:环状RNA circMET通过miR-30-5p/snail/DPP4轴驱动肝细胞癌的免疫抑制和抗PD-1治疗耐药。

Huang, Xiao-Yong; Zhang, Peng-Fei; Wei, Chuan-Yuan; Peng, Rui; Lu, Jia-Cheng; Gao, Chao; Cai, Jia-Bing; Yang, Xuan; Fan, Jia; Ke, Ai-Wu; Zhou, Jian; Shi, Guo-Ming

Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors

基于单细胞RNA的生物启发式图神经网络在原发性肝肿瘤诊断中的应用

Zhang, Dao-Han; Liang, Chen; Hu, Shu-Yang; Huang, Xiao-Yong; Yu, Lei; Meng, Xian-Long; Guo, Xiao-Jun; Zeng, Hai-Ying; Chen, Zhen; Zhang, Lv; Pei, Yan-Zi; Ye, Mu; Cai, Jia-Bin; Huang, Pei-Xin; Shi, Ying-Hong; Ke, Ai-Wu; Chen, Yi; Ji, Yuan; Shi, Yujiang Geno; Zhou, Jian; Fan, Jia; Yang, Guo-Huan; Sun, Qi-Man; Shi, Guo-Ming; Lu, Jia-Cheng

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

托瑞普利单抗联合乐伐替尼和吉西他滨方案作为晚期肝内胆管癌的一线治疗方案前景可观:一项单中心、单臂 II 期研究

Shi, Guo-Ming; Huang, Xiao-Yong; Wu, Dong; Sun, Hui-Chuan; Liang, Fei; Ji, Yuan; Chen, Yi; Yang, Guo-Huan; Lu, Jia-Cheng; Meng, Xian-Long; Wang, Xin-Ying; Sun, Lei; Ge, Ning-Ling; Huang, Xiao-Wu; Qiu, Shuang-Jian; Yang, Xin-Rong; Gao, Qiang; He, Yi-Feng; Xu, Yang; Sun, Jian; Ren, Zheng-Gang; Fan, Jia; Zhou, Jian

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)

肝内胆管癌病理诊断专家共识(2022版)

Wang, Han; Chen, Jun; Zhang, Xin; Sheng, Xia; Chang, Xiao-Yan; Chen, Jie; Chen, Min-Shan; Dong, Hui; Duan, Guang-Jie; Hu, He-Ping; Huang, Zhi-Yong; Jia, Wei-Dong; Jiang, Xiao-Qing; Kuang, Dong; Li, Shan-Shan; Li, Zeng-Shan; Lu, Chang-Li; Qin, Shu-Kui; Qiu, Xue-Shan; Qu, Li-Juan; Shao, Chun-Kui; Shen, Feng; Shi, Guo-Ming; Shi, Su-Sheng; Shi, Yu-Jun; Sun, Hui-Chuan; Teng, Xiao-Dong; Wang, Bin; Wang, Zhan-Bo; Wen, Tian-Fu; Yang, Jia-Mei; Yang, Qiao-Qiao; Ye, Sheng-Long; Yin, Hong-Fang; Yuan, Zhen-Gang; Yun, Jing-Ping; Zang, Feng-Lin; Zhang, Hong-Qi; Zhang, Li-Hong; Zhao, Jing-Min; Zhou, Jian; Zhou, Wei-Xun; Fan, Jia; Chen, Xiao-Ping; Lau, Wan Yee; Ji, Yuan; Cong, Wen-Ming

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

培米替尼治疗既往接受过治疗的携带FGFR2融合或重排的局部晚期或转移性胆管癌中国患者:一项II期研究

Shi, Guo-Ming; Huang, Xiao-Yong; Wen, Tian-Fu; Song, Tian-Qiang; Kuang, Ming; Mou, Hai-Bo; Bao, Le-Qun; Zhao, Hai-Tao; Zhao, Hong; Feng, Xie-Lin; Zhang, Bi-Xiang; Peng, Tao; Zhang, Yu-Bao; Li, Xiang-Cheng; Yu, Hong-Sheng; Cao, Yu; Liu, Lian-Xin; Zhang, Ti; Wang, Wei-Lin; Ran, Jiang-Hua; Liu, Ying-Bin; Gong, Wei; Chen, Ming-Xia; Cao, Lian; Luo, Yang; Wang, Yan; Zhou, Hui; Yang, Guo-Huan; Fan, Jia; Zhou, Jian

Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis

个体化通路活性算法可识别泛癌分析中的致癌通路

Ke, Xin; Wu, Hao; Chen, Yi-Xiao; Guo, Yan; Yao, Shi; Guo, Ming-Rui; Duan, Yuan-Yuan; Wang, Nai-Ning; Shi, Wei; Wang, Chen; Dong, Shan-Shan; Kang, Huafeng; Dai, Zhijun; Yang, Tie-Lin

Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

阿伐曲波帕治疗伴有严重血小板减少症的肝癌患者的有效性和安全性:真实世界数据和挑战

Huang, Ao; Chen, Jia-Feng; Wu, Jian-Zhang; Gao, Zheng; Shi, Ying-Hong; Fu, Xiu-Tao; Zhang, Xin; Liu, Wei-Ren; Gao, Qiang; Sun, Hui-Chuan; Shi, Guo-Ming; Fan, Jia; Ding, Zhen-Bin; Zhou, Jian